Tema Heart & Health ETF (NASDAQ:HRTS) Shares Down 0.2% – Time to Sell?

Tema Heart & Health ETF (NASDAQ:HRTS)’s stock price traded down 0.2% on Monday . The stock traded as low as $35.50 and last traded at $35.59. 2,551 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 9,290 shares. The stock had previously closed at $35.65.

Tema Heart & Health ETF Stock Performance

The company’s 50-day moving average price is $35.58 and its 200 day moving average price is $32.80. The stock has a market capitalization of $56.59 million, a PE ratio of 22.06 and a beta of 0.97.

Tema Heart & Health ETF Announces Dividend

The company also recently announced a dividend, which was paid on Thursday, December 11th. Shareholders of record on Wednesday, December 10th were issued a dividend of $0.4729 per share. The ex-dividend date was Wednesday, December 10th.

Institutional Investors Weigh In On Tema Heart & Health ETF

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HRTS. JPMorgan Chase & Co. purchased a new position in Tema Heart & Health ETF during the second quarter valued at $63,000. Jane Street Group LLC lifted its position in Tema Heart & Health ETF by 9.4% during the 2nd quarter. Jane Street Group LLC now owns 37,164 shares of the company’s stock valued at $1,062,000 after acquiring an additional 3,202 shares during the period. CoreCap Advisors LLC boosted its stake in Tema Heart & Health ETF by 25,280.4% during the third quarter. CoreCap Advisors LLC now owns 51,776 shares of the company’s stock worth $1,602,000 after acquiring an additional 51,572 shares in the last quarter. Citadel Advisors LLC bought a new stake in Tema Heart & Health ETF during the third quarter worth about $243,000. Finally, Brookstone Capital Management purchased a new stake in Tema Heart & Health ETF in the fourth quarter worth about $364,000.

About Tema Heart & Health ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.